KOL Mapping for Market Access: Identifying the Experts Who Shape Payer and Access Decisions
Market AccessKEE MappingHTAPayer Intelligence
Reimbursement decisions are not made in a vacuum. They are shaped by a network of health economists, HTA committee members, payer advisors, patient advocacy organisations, clinical guideline leaders, and healthcare policymakers — all of whom hold positions on value evidence, comparative effectiveness, and cost-effectiveness thresholds that directly affect your therapy’s access prospects. KOL Mapping by VML maps this network for you.
🔸 The Market Access Expert Intelligence Gap
- Standard KOL mapping focuses on prescribing physicians — missing the payer and HTA experts whose decisions determine whether patients can actually access the therapy
- HTA committee members, health economists, and payer advisors operate in networks that are largely invisible to clinical KOL mapping approaches
- Patient advocacy organisations — increasingly influential in HTA processes — are rarely included in traditional expert mapping programmes
- The positions of key payer influencers on value evidence, QALY thresholds, and comparative effectiveness are unknown until the HTA submission — too late to influence
- Catalysts driving shifts in HTA methodology and reimbursement policy are identified reactively, after they have already reshaped the access landscape
✓ How KOL Mapping by VML Supports Market Access Teams
- KEE identification covering the full market access influencer landscape — HTA experts, health economists, payer advisors, patient advocates, and policy leaders
- Expert position profiles showing current views on value evidence standards, QALY thresholds, and comparative effectiveness methodology
- Influence mapping showing how clinical KOLs, health economists, and HTA decision-makers interact — revealing the network pathways through which clinical evidence reaches access decisions
- Catalyst of change mapping identifying the experts driving shifts in HTA methodology and payer policy before those shifts become formally adopted
- Geography-specific coverage — HTA landscapes differ significantly between NICE, HAS, IQWIG, FDA/CMS, and regional bodies; each requires market-specific expertise
The Market Access Expert Landscape: Who Matters
| Expert Type | Role in Access Decisions | KOL Mapping Module |
|---|---|---|
| HTA committee members | Directly vote on reimbursement recommendations; their positions on evidence standards are determinative | Established Leader Mapping |
| Health economists | Design and critique the economic models that underpin HTA submissions; their methodological positions shape what evidence is accepted | Established Leader Mapping |
| Clinical guideline leaders | Guideline recommendations directly inform payer coverage decisions; their positions affect what payers consider standard of care | Established Leader Mapping + Catalyst Mapping |
| Patient advocacy leaders | Increasingly influential in HTA processes; patient voice in dossier submissions and committee hearings shapes outcomes | Catalyst of Change Mapping |
| Healthcare policymakers | Shape the regulatory and reimbursement environment within which HTA operates; early intelligence on policy shifts enables proactive positioning | Catalyst of Change Mapping |
| Digital health policy influencers | Shape the policy discourse on real-world evidence, digital therapeutics, and value-based contracting that increasingly affects access decisions | DOL Mapping |
Frequently Asked Questions
Can KOL Mapping by VML map the expert landscape for HTA submissions in specific countries?
Yes. HTA and payer expert landscapes vary significantly between countries — NICE in the UK, HAS in France, IQWIG in Germany, TLV in Sweden, and others all operate with different committee compositions, methodological frameworks, and key influencer networks. KOL Mapping by VML provides country-specific coverage using local data sources and expertise, ensuring that the expert intelligence reflects the specific access decision-making environment of each target market. → Discuss country-specific market access mapping
How far in advance of an HTA submission should market access expert mapping be commissioned?
Ideally 18–24 months before submission — providing enough time to understand committee member positions, identify the health economists and patient advocates most likely to influence the process, and develop relationships and evidence strategies that reflect those positions. Commissioning mapping 6 months before submission gives intelligence but insufficient time to act on it strategically. → Read: KEE Mapping for Pharma